Search results

  • International Women’s Day 2023

    International Women’s Day (IWD) is a global day of reflection, but it’s also a day of action that calls us to move gender parity farther and faster. A few of us at Legend Biotech sat down to consider this year’s IWD theme, “#EmbraceEquity”, which encourages societies to move beyond equality and strive for equity. As […]

  • International Women’s Day 2023

    International Women’s Day (IWD) is a global day of reflection, but it’s also a day of action that calls us to move gender parity farther and faster. A few of us at Legend Biotech sat down to consider this year’s IWD theme, “#EmbraceEquity”, which encourages societies to move beyond equality and strive for equity. As […]

  • Legend Biotech Announces Participation in Upcoming Investor Conferences

    SOMERSET, N.J.— February 24, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences: Event: Cowen 43rd Annual Healthcare ConferenceLocation: Boston, MAFireside Chat Date & Time: Tuesday, March 7, 2023 at 9:50am ETPresenter: Ying Huang, […]

  • Legend Biotech Regains Compliance with NASDAQ Listing Rule 5250(c)(2) 

    Somerset, N.J.—February 21, 2023—Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced that it received notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) on February 17, 2023 indicating that the Company has regained compliance with […]

  • Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI®(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

    CARTITUDE-4, the Phase 3 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) compared to standard therapy, has met its primary endpoint.

  • Legend Biotech Announces Notification of Delinquency from The Nasdaq Stock Market LLC

    Somerset, N.J.—January 10, 2023—Legend Biotech Corporation (“Legend Biotech” or the “Company”) (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that it received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on January 6, 2023 indicating that the […]

  • Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference

    Somerset, N.J.—January 3, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. CEO Ying Huang, Ph.D. will deliver the company presentation on Tuesday, January 10, 2023 at […]

  • Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

    China’s National Medical Products Administration (NMPA) has formally accepted its New Drug Application (NDA) for ciltacabtagene autoleucel (cilta-cel).

  • Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

    Somerset, N.J.—November 21, 2022—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared Legend Biotech’s Investigational New Drug (IND) application to proceed with the clinical development of LB2102, an investigational, autologous chimeric […]

close

You are about to leave LegendBiotech.com

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.